Liu Jingzhen: Forging Global Competitiveness with a "Big Country" in Mind

The leaps and bounds of the times have completely changed China's pharmaceutical industry.
Industry giants have come and gone, but there are very few "big powers and heavy weapons" on their shoulders
.

On September 25, Sinopharm's China Biotech mRNA vaccine industrialization base started in Shanghai.

2021 is the first year of the national "14th Five-Year Plan" and also the year of the comprehensive internationalization of China's pharmaceutical industry
.

As the “eldest son of the Republic” of China’s pharmaceutical industry, Sinopharm has persisted in fighting the epidemic with one hand and unremitting efforts in innovation and development in the past year, winning the “double victory” of epidemic prevention and control and innovative development

The mission of the industry "national team"is

The mission of the industry "national team"is

The task of preventing and controlling the new crown epidemic is arduous.
Sinopharm has risen to the challenge, demonstrating China's speed and wisdom, and also demonstrating China's mission and responsibility
.

In terms of taking advantage of the medical circulation system to ensure emergency supply, Sinopharm relies on the huge medical logistics system covering the whole country, utilizes the advantages of commercial network, and in accordance with the central medical reserve allocation instructions, completes task deployment, supply organization, transportation and distribution in the shortest time.

Liu Jingzhen, Chairman and Party Secretary of Sinopharm Group, pointed out that Sinopharm puts national public health safety and people’s lives and health first, fulfills the social responsibilities of central enterprises, actively organizes mobilization in a wartime state, and gives full play to the "national team" and "national team" of the industrial front.
As the main force, we will make every effort to do a good job in the emergency allocation and supply of medical materials, diagnostic reagents, drug vaccine research and development, emergency production, medical treatment and epidemic prevention guarantees
.

Liu Jingzhen, Chairman and Party Secretary of Sinopharm Group

In terms of giving full play to the production capacity advantages of production enterprises to guarantee urgent needs, the National Health Commission’s "New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Version 7)" recommends a total of 105 varieties of drugs, and Sinopharm can independently produce 91 varieties
.

Throughout the fight against the epidemic, the production companies of the Sinopharm Group resumed production in an emergency.

In terms of giving full play to the professional advantages of medical institutions, 139 medical institutions and more than 20,000 medical staff of Sinopharm Group have all participated in medical treatment, especially the more than 4,200 medical staff of 6 medical institutions in Hubei.
The forefront of control; Sinopharm Dongfeng General Hospital creatively used hyperbaric oxygen to treat patients with new coronary pneumonia, and achieved good results
.

Sinopharm Group resolutely fulfills its responsibilities as a central enterprise, takes "caring for life and caring for health" as its core philosophy, and keeps its promises without ambiguity
.

There are more than 9,000 retail pharmacies under Sinopharm Group, and when the market supply is very tight, it takes the lead to make a solemn promise: "Never increase prices! Guarantee quality!" All pharmaceutical products are sold at par, and there are 58 designated pharmacies in Beijing alone.

Liu Jingzhen believes that it is necessary to meet the needs of public health system construction and better guarantee emergency medical supplies according to the new situation and new problems of disasters, epidemics, and emergencies; focus on multiple major links such as production, storage, procurement, and supply, and it must be adequate Give full play to the core role of information, and establish an emergency material guarantee system with central, local, and enterprise unified leadership, hierarchical division of labor, coordinated linkage, and dynamic adjustment
.

Facing the "crisis" and "machine",  independent research and development to escort

Facing the "crisis" and "machine",  independent research and development to escort

In the face of major changes unseen in a century, it is the responsibility of the central state-owned enterprises of the big country to be anxious about what the party thinks, what the country wants, and what the people want
.

Sinopharm Group takes the protection of people’s lives and health as its practical goal.

There is no doubt that the impact of the epidemic is a crisis test, but “danger” and “opportunities” coexist.
To seize opportunities, we must be guided by innovative development concepts, driven by technological breakthroughs, and facing the needs of industrial upgrading for high-quality development.
Promote the continuous development and optimization of pharmaceutical technology and service models through technological innovation
.

At the critical moment, the major powers have stepped onto the battlefield of fighting the epidemic, and independent innovation technologies have come in handy
.

Taking advantage of the scientific and technological advantages of drug research and development, Sinopharm Group immediately established a research and development team to organize a medical research team in a wartime state to obtain rapid and portable nucleic acid detection kits, plasma treatment methods for recovered patients, specific immunoglobulins and inactivation A series of major innovations that lead the world, marked by vaccines

At the beginning of the epidemic, Sinopharm sent a scientific research team to Wuhan as soon as possible, and successfully developed a new coronavirus nucleic acid test kit within 48 hours, becoming the first batch of test reagent products recommended by the National Medical Products Administration
.

Liu Jingzhen said that Sinopharm is based on the development platform of the pharmaceutical health industry, faithfully fulfills the political, social, economic, and international responsibilities of central enterprises, and uses the strength of the entire group to integrate the advantages of the entire industry chain and strive to win epidemic prevention and control and production and operation.
Double victories, striving to create a world-class pharmaceutical enterprise group with outstanding global competitiveness, and make new and greater contributions to building a "healthy China" and building a well-off society in an all-round way
.

As a major country assumes its responsibility, China’s innovation is emboldened

As a major country assumes its responsibility, China’s innovation is emboldened

The big country heavy equipment is emboldened
.

Based on the new development stage, implementing the new development concept, building a new development pattern, and promoting high-quality development, we need to examine the opportunities and tests of the innovation and upgrading of the local pharmaceutical industry and the internationalization in the new situation with a comprehensive, dialectical, and long-term perspective

Run out of China's innovation speed, and export China's innovation standards
.
In the early stage of the outbreak, when there was no specific medicine, Sinopharm took the lead in proposing plasma therapy for convalescent patients in China
.
In April last year, the Proceedings of the National Academy of Sciences published a research paper on the recovery period plasma therapy of Sinopharm Group Sinopharm Group, which attracted the attention of the global medical community; the recovery period plasma therapy "out of the country" in many countries and regions The promotion of use has saved more lives
.

Clouds and waters are raging around the world, and the five continents are shaking and thunderous
.
In the first half of this year, to promote the domestic and international dual cycle, Sinopharm implemented international cooperation in China's pharmaceutical industry and actively participated in the special procurement plan of the World Health Organization
.
In addition, Sinopharm also signed a memorandum of industrial cooperation with the Serbian government and the UAE G42 Group.
In September this year, it landed the first Chinese vaccine factory in Europe in Serbia
.

Recently, Sinopharm Group has developed four new crown vaccines, including three diagnostic reagents in the "diagnosable" field, two specific drugs in the "curable" field, and three technical routes in the "preventable" field in the fight against the new crown pneumonia epidemic, a total of 9 products.
, Respectively at the 2021 China International Trade in Services Fair, the 2nd China-Africa Economic and Trade Expo and Dubai World Expo
.
Sinopharm Group is going all-out to contribute Chinese wisdom and strength to the global fight against the epidemic and the construction of a human health and health community with more scientific and technological innovations
.

When the sky falls, it can be supported, and the world is invincible
.
On August 2, 2021, "Fortune" released the 2021 "Fortune 500" list, and Sinopharm ranked 109th.
This is the ninth consecutive year that Sinopharm has been included in the "Fortune" Fortune 500 list; since 2013 Since entering the list for the first time in 2015, Sinopharm Group has continuously improved its ranking and has risen to 337 places so far
.

Liu Jingzhen said that the new journey is inspiring and the new goals are inspiring.
Sinopharm Group will uphold the corporate philosophy of "caring for life and care for health", with the "big nation" in mind, vigorously promote the spirit of the new era of Sinopharm, and go all out to promote the "four beams and eight pillars, "Top Hundred Trillion" innovation-driven, accelerate the in-depth implementation of the overall development strategy of the entire life cycle, the entire industry chain, and the entire ecosystem, and make strides forward on the new journey of building a world-class comprehensive medical and health industry group with global competitiveness
.